Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 19 recruiting now early-phase tilt

Non-alcoholic Fatty Liver Disease: early-phase trial registry

19 of 58 indexed Non-alcoholic Fatty Liver Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #244 of 28,707 conditions by registered trial count.

58 US clinical trials · 19 currently recruiting · #244 of 28,707 conditions by registered trial count

Non-alcoholic Fatty Liver Disease: 58 US clinical trials tracked, 19 recruiting.

Non-alcoholic Fatty Liver Disease is the subject of 58 registered US clinical trials on ClinicalTrials.gov, 19 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 3 of these trials.

Enrollment posture brief

Registry condition non-alcoholic-fatty-liver-disease

OPEN 19 | RECR 33% | LATE 7 | EARLY 22 | RANK #244 | SPON 3

Nearest open-share peer: Diabetes Mellitus, Type 1 (33% recruiting · 119 trials)

Recurrent Acute Myeloid Leuk51.7%Anesthesia43.1%Exercise41.4%Non-alcoholic Fatty Live (th…33%Diabetic Retinopathy25.9%
Open-enrollment share among volume-matched conditions near Non-alcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease lists 19 open slots (33% of 58 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Non-alcoholic Fatty Liver Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Non-alcoholic Fatty Liver Disease is recruiting below its size-band peers.

    19 of 58 indexed trials (32.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Non-alcoholic Fatty Liver Disease trials is spread across many organizations.

    Pfizer accounts for 3 of 58 trials (5.2%). 46 distinct sponsors appear on at least one study for this condition label.

  3. Most Non-alcoholic Fatty Liver Disease trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 58 trials that report a genuine target (sentinel values excluded). 39 of those (67.2%) plan for fewer than 100 participants.

  4. Non-alcoholic Fatty Liver Disease research is mostly interventional.

    48 interventional and 10 observational studies make up this index (82.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 217Phase 34Phase 43

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 17
Phase 3 4
Phase 4 3

Named interventions

Most-linked intervention names on Non-alcoholic Fatty Liver Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
13 trials
PF-05221304 Drug
2 trials
PF-06865571 Drug
2 trials
Placebo Other
2 trials
Usual standard of care Behavioral
1 trials
Healthy Liver/Hígado Sano program Behavioral
1 trials
Pioglitazone Open Label Drug
1 trials
Pioglitazone study drug Drug
1 trials

US sites by state

Facility locations filed on Non-alcoholic Fatty Liver Disease trials. A trial with sites in several states counts in each.

Florida 16 trials
California 16 trials
Texas 15 trials
Arizona 8 trials
Georgia 7 trials
Ohio 6 trials
Massachusetts 5 trials
Colorado 5 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Non-alcoholic Fatty Liver Disease page

58 registered trials, 19 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 19 Non-alcoholic Fatty Liver Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Pfizer sponsors the most Non-alcoholic Fatty Liver Disease trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-alcoholic Fatty Liver Disease condition card totals 58 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.